This partnership enhances NRXP's care delivery model with a scalable, data-driven tool that could improve clinical outcomes and differentiate its clinic network. Traders should monitor for future monetization pathways, such as licensing the platform or bundling it with treatments. Watch for upcoming clinical trial results validating real-world efficacy.
Price Chart
Executive Summary
NRx Pharmaceuticals' subsidiary Hope Therapeutics partnered with Emobot Health to deploy an AI-powered 'Depression Thermometer' across its interventional psychiatry clinics. The technology enables passive, real-time monitoring of depression and anxiety via smartphone, aiming to reduce relapse rates and improve patient outcomes through early intervention.
Key Facts
- Hope Therapeutics (NRXP subsidiary) partnered with Emobot Health to integrate AI-driven emotional monitoring in its clinic network.
- Emobot's 'Depression Thermometer' passively analyzes facial expressions, vocal tones, and actigraphy to detect early relapse in TRD patients.
- Clinical validation shows strong correlation with MADRS (r=0.89) and PHQ-9 (r=0.83) scales.
- The platform aims to double patient success rates by enabling timely recapture interventions like maintenance ketamine or TMS.
- Patients receive real-time mood insights and can reschedule appointments in-app upon relapse detection.
Financial Impact
No direct financial figures disclosed; potential long-term revenue upside from improved patient retention and expanded digital health offering.
Risk Factors
- No immediate revenue impact; commercial benefits are forward-looking and dependent on adoption and clinical outcomes.
- Regulatory scrutiny may arise if the AI platform is deemed a medical device requiring FDA clearance.
- Forward-looking statements dominate the release — actual performance may not match expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access